In its latest report, the firm notes that pharmaceutical companies are still shedding non-core assets with the aim to specialise, gain access to new technology and grow their product pipelines.
SINGAPORE (Jan 7): Dealmaking in the global healthcare sector is forecast to rise modestly this year after 2019 “started with a bang” with news of US pharmaceutical giant Bristol-Myers Squibb’s intended acquisition of Celgene for US$74 billion ($100.5 billion).
This is according to Baker McKenzie’s Global Transactions Forecast report for 2019, which predicts a rise of 7% to US$331 billion this year – notwithstanding the BMS-Celgene tie-up – after the healthcare sector registered a 5% drop to US$308 billion in 2018.
